Replimune Announces Staff Cuts, MeiraGTx Reacquires Eye Gene Therapy
Replimune is cutting 63 jobs due to the FDA rejecting its melanoma therapy RP1 and financial constraints. Meanwhile, MeiraGTx has reacquired rights to a gene therapy for retinitis pigmentosa from Johnson & Johnson and raised $100 million in equity. These developments reflect challenges in drug approvals and strategic repositioning in the biotech sector.
Topics: Biotech Gene Therapy Layoffs M&A Regulatory Approval